|
May 13
|
Fate Therapeutics, Inc. (NASDAQ:FATE) Q1 2024 Earnings Call Transcript
|
|
May 11
|
Fate Therapeutics First Quarter 2024 Earnings: Revenues Beat Expectations, EPS In Line
|
|
May 10
|
Fate Therapeutics Inc (FATE) Q1 2024 Earnings: Mixed Financial Performance Amid Clinical ...
|
|
May 9
|
Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates
|
|
May 9
|
Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
|
|
May 9
|
Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program
|
|
May 6
|
Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2024 Financial Results and Operational Updates
|
|
May 3
|
Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting
|
|
Apr 22
|
Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting
|
|
Apr 6
|
Fate Therapeutics (FATE) Surges 86.4% YTD on Pipeline Progress
|
|
Apr 3
|
Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference
|
|
Mar 29
|
Why Is Amicus Therapeutics (FOLD) Down 8.1% Since Last Earnings Report?
|
|
Mar 28
|
Why Is Myriad (MYGN) Down 1% Since Last Earnings Report?
|
|
Mar 27
|
Fate Therapeutics (FATE) Down 8% Since Last Earnings Report: Can It Rebound?
|
|
Mar 19
|
Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement
|
|
Mar 5
|
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
|
|
Jan 8
|
Fate Therapeutics Announces Initiation of Phase 1 Clinical Trial for FT825 / ONO-8250 in Patients with HER2-expressing Advanced Solid Tumors
|
|
Dec 29
|
Fate Therapeutics Insiders US$207k Short Of Breakeven On Stock Purchase
|
|
Dec 22
|
Fate Therapeutics (FATE) Upgraded to Buy: Here's Why
|
|
Dec 18
|
12 Most Promising Cancer Stocks According to Analysts
|